ICTUImperial Clinical Trials Unit

Welcome to Imperial Clinical Trials Unit (ICTU)

This website is intended for commercial trial sponsors engaged in the area of pharmaceuticals, medical devices or diagnostic devices

Clinical Trials Search


CurrentAll Trials


Trial Details

Nucleos(t)ide withdrawal in HBeAg negative hepatitis B virus infection to promote HBsAg clearance

Design and Objective

NUC-B will be a multicentre, randomised, open label trial comparing two management strategies to promote HBsAg loss in patients with HBeAg negative chronic HBV infection.

Key inclusion criteria

• Age ≥ 18 • Chronic HBV infection • HBeAg negative • Nucleos(t)ide analogues treatment for ≥3 years • HBV DNA < 400 IU/ml ≥2 years • Informed consent

Study Disclaimer Statement